44 results
8-K
EX-99.1
TSHA
Taysha Gene Therapies Inc
19 Mar 24
Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates
4:17pm
patient in REVEAL Phase 1/2 trial showed TSHA-102 (low dose, 5.7x1014 total vg) was well-tolerated with no treatment-emergent SAEs as of 35-week assessment … patient showed TSHA-102 (low dose, 5.7x1014 total vg) was well-tolerated with no treatment-emergent SAEs as of 19-week assessment, with sustained
8-K
EX-99.1
TSHA
Taysha Gene Therapies Inc
14 Nov 23
Taysha Gene Therapies Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates
4:47pm
patient in REVEAL Phase 1/2 trial showed TSHA-102 was well-tolerated with no treatment-emergent SAEs as of 20-week assessment with sustained … second adult patient showed TSHA-102 was well-tolerated with no treatment-emergent SAEs as of six-week assessment with improvement across key
424B3
vb3n4fljt1kh5lgnw10
11 Sep 23
Prospectus supplement
4:01pm
8-K
EX-10.1
8j3r8
14 Aug 23
Entry into a Material Definitive Agreement
7:29am
8-K
EX-99.1
g3m5 mf7agte
14 Aug 23
Entry into a Material Definitive Agreement
7:29am
PRE 14A
ayipmof 7ueuk
27 Apr 23
Preliminary proxy
4:03pm